Performance Testing for Dry Powder Inhaler Products: Towards Clinical Relevance
Source abstract
Abstract
It is well established that the critical performance metrics for aerosol products are aerodynamic particle size distribution (APSD) and delivered dose uniformity (DDU). In broad terms, these performance characteristics dictate the efficiency and reproducibility with which an aerosol is administered clinically. However, these properties alone do not support in-vitro, in-vivo correlations. There have been numerous publications attempting to more directly link product performance testing to physiological relevance or further to draw direct correlations of relevance to bioequivalence testing for the development of generic products. While these novel methods have been employed in product development activity, their suitability for compendial testing has yet to be established. This paper explores the potential to establish biologically relevant compendial standards for dry powder inhaler products while maintaining accuracy and reproducibility of data collected to support the quality and performance of the product.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Inhalation and Respiratory Drug Delivery · Drug Solubulity and Delivery Systems · Microencapsulation and Drying Processes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
RTI International, Research Triangle Park, USA
Funding
RTI International
References (58)
Show source-provided references
1. Adams W.P., Ahrens R.C., Chen M.-L., Christopher D., Chowdhury B.A., Conner D.P., Dalby R., Fitzgerald K., Hendeles L., Hickey A.J., Hochhaus G., Laube B.L., Lucas P., Lee S.L., Lyapustina S., et al.., Demonstrating bioequivalence of locally acting orally inhaled drug products (OIPs): workshop summary report, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 23 (2010) 1–29. DOI:10.1089/jamp.2009.080310.1089/jamp.2009.0803 ↗
2. Adams W.P., Christopher D., Lee D.S., Morgan B., Pan Z., Singh G.J.P., Tsong Y., Lyapustina S., Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 1: background for a statistical method, AAPS PharmSciTech, 8 (2007) E1–E6. DOI:10.1208/pt080100410.1208/pt0801004 ↗
3. Alagusundaram M., Deepthi N., Ramkanth S., Angalaparameswari S., Saleem T.S.M., Gnanaprakash K., Thiruvengadarajan V.S., Chetty C.M., Dry powder inhalers—an overview, International Journal of Research in Pharmaceutical Sciences, 1 (2010) 34–42.
4. Apiou-Sbirlea G., Newman S., Fleming J., Siekmeier R., Ehrmann S., Scheuch G., Houchhaus G., Hickey A., Bioequivalence of inhaled drugs: fundamentals, challenges and perspectives, Therapeutic Delivery, 4 (2013) 343–367. DOI:10.4155/tde.12.16110.4155/tde.12.161 ↗
5. Bäckman P., Cabal A., Clark A., Ehrhardt C., Forbes B., Hastedt J., Hickey A., Hochhaus G., Jiang W., Kassinos S., Kuehl P.J., Prime D., Son Y.-J., Teague S.P., Tehler U., et al., iBCS: 2. Mechanistic modeling of pulmonary availability of inhaled drugs versus critical product attributes, Molecular Pharmaceutics, 19 (2022) 2040–2047. DOI:10.1021/acs.molpharmaceut.2c0011210.1021/acs.molpharmaceut.2c00112 ↗
6. Below A., Bickmann D., Breitkreutz J., Assessing the performance of two dry powder inhalers in preschool children using an idealized pediatric upper airway model, International Journal of Pharmaceutics, 444 (2013) 169–174. DOI:10.1016/j.ijpharm.2013.01.00710.1016/j.ijpharm.2013.01.007 ↗
7. Brunaugh A.D., Jan S.U., Ferrati S., Smyth H.D.C., Excipient-free pulmonary delivery and macrophage targeting of clofazimine via air jet micronization, Molecular Pharmaceutics, 14 (2017) 4019–4031. DOI:10.1021/acs.molpharmaceut.7b0069010.1021/acs.molpharmaceut.7b00690 ↗
8. Buttini F., Brambilla G., Copelli D., Sisti V., Balducci A.G., Bettini R., Pasquali I., Effect of flow rate on in vitro aerodynamic performance of NEXThaler® in comparison with Diskus® and Turbohaler® dry powder inhalers, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 29 (2016) 167–178. DOI:10.1089/jamp.2015.122010.1089/jamp.2015.1220 ↗
9. Chaurasiya B., Zhao Y.-Y., Dry powder for pulmonary delivery: a comprehensive review, Pharmaceutics, 13 (2021) 31. DOI:10.3390/pharmaceutics1301003110.3390/pharmaceutics13010031 ↗
10. Cheng Y.S., Mechanisms of pharmaceutical aerosol deposition in the respiratory tract, AAPS PharmSciTech, 15 (2014) 630–640. DOI:10.1208/s12249-014-0092-010.1208/s12249-014-0092-0 ↗
11. Chow M.Y.T., Tai W., Chang R.Y.K., Chan H.-K., Kwok P.C.L., In vitro-in vivo correlation of cascade impactor data for orally inhaled pharmaceutical aerosols, Advanced Drug Delivery Reviews, 177 (2021) 113952. DOI:10.1016/j.addr.2021.11395210.1016/j.addr.2021.113952 ↗
12. Christopher D., Adams W., Amann A., Bertha C., Byron P.R., Doub W., Dunbar C., Hauck W., Lyapustina S., Mitchell J., Morgan B., Nichols S., Pan Z., Pal Singh G.J., Tougas T., et al.., Product quality research institute evaluation of cascade impactor profiles of pharmaceutical aerosols, part 3: final report on a statistical procedure for determining equivalence, AAPS PharmSciTech, 8 (2007a) 65. DOI:10.1208/pt080409010.1208/pt0804090 ↗
13. Christopher D., Adams W.P., Lee D.S., Morgan B., Pan Z., Singh G.J.P., Tsong Y., Lyapustina S., Product Quality Research Institute evaluation of cascade impactor profiles of pharmaceutical aerosols: part 2—evaluation of a method for determining equivalence, AAPS PharmSciTech, 8 (2007b) E39–E48. DOI:10.1208/pt080100510.1208/pt0801005 ↗
14. Clark A.R., Understanding penetration index measurements and regional lung targeting, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 25 (2012) 179–187. DOI:10.1089/jamp.2011.089910.1089/jamp.2011.0899 ↗
15. Clark A.R., Hollingworth A.M., The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers—implications for in vitro testing, Journal of Aerosol Medicine, 6 (1993) 99–110. DOI:10.1089/jam.1993.6.9910.1089/jam.1993.6.99 ↗
16. Coates M.S., Chan H.-K., Fletcher D.F., Raper J.A., Influence of air flow on the performance of a dry powder inhaler using computational and experimental analyses, Pharmaceutical Research, 22 (2005) 1445–1453. DOI:10.1007/s11095-005-6155-x10.1007/s11095-005-6155-x ↗
17. de Boer A.H., Gjaltema D., Frijlink P.H.H.W., Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique, International Journal of Pharmaceutics, 249 (2002) 219–231. DOI:10.1016/S0378-5173(02)00526-410.1016/S0378-5173(02)00526-4 ↗
18. Dolovich M.B., Kuttler A., Dimke T.J., Usmani O.S., Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler, International Journal of Pharmaceutics: X, 1 (2019) 100018. DOI:10.1016/j.ijpx.2019.10001810.1016/j.ijpx.2019.100018 ↗
19. Dunbar C.A., Hickey A.J., Holzner P., Dispersion and characterization of pharmaceutical dry powder aerosols, KONA Powder and Particle Journal, 16 (1998) 7–45. DOI:10.14356/kona.199800710.14356/kona.1998007 ↗
20. EMEA (European Medicines Agency), Pre-authorisation evaluation of medicines for human use, European Medicines Agency, London, 2009. accessed 20.07.2022.
21. Engstrom J.D., Lai E.S., Ludher B.S., Chen B., Milner T.E., III R.O.W., Kitto G.B., Johnston K.P., Formation of stable submicron protein particles by thin film freezing, Pharmaceutical Research, 25 (2008) 1334–1346. DOI:10.1007/s11095-008-9540-410.1007/s11095-008-9540-4 ↗
22. Finlay W.H., Darquenne C., Particle size distributions, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 33 (2020) 178–180. DOI:10.1089/jamp.2020.29028.whf10.1089/jamp.2020.29028.whf ↗
23. Frohlich E., Biological obstacles for identifying in vitro-in vivo correlations of orally inhaled formulations, Pharmaceutics, 11 (2019) 316. DOI:10.3390/pharmaceutics1107031610.3390/pharmaceutics11070316 ↗
24. Gradon L., Sosnowski T.R., Formation of particles for dry powder inhalers, Advanced Powder Technology, 25 (2014) 43–55. DOI:10.1016/j.apt.2013.09.01210.1016/j.apt.2013.09.012 ↗
25. Hastedt J.E., Bäckman P., Cabal A., Clark A., Ehrhardt C., Forbes B., Hickey A.J., Hochhaus G., Jiang W., Kassinos S., Kuehl P.J., Prime D., Son Y.-J., Teague S., Tehler U., et al.., iBCS: 1. Principles and framework of an inhalation-based biopharmaceutics classification system, Molecular Pharmaceutics, 19 (2022) 2032–2039. DOI:10.1021/acs.molpharmaceut.2c0011310.1021/acs.molpharmaceut.2c00113 ↗
26. Hastedt J.E., Bäckman P., Clark A.R., Doub W., Hickey A., Hochhaus G., Kuehl P.J., Lehr C.-M., Mauser P., McConville J., Niven R., Sakagimi M., Weers J.G., Scope and relevance of a pulmonary biopharmaceutical classification system AAPS/FDA/USP Workshop March 16–17th, 2015 in Baltimore, MD, AAPS Open, 2 (2016) 1(20pp). DOI:10.1186/s41120-015-0002-x10.1186/s41120-015-0002-x ↗
27. Hickey A.J., Fundamentals of dry powder inhaler technology, in: Merkus H.G., Meesters G.M.H., Oostra W. (Eds.), Particles and Nanoparticles in Pharmaceutical Products: Design, Manufacturing, Behavior and Performance, Springer International Publishing, Cham, 2018a, pp. 213–232, ISBN: 978-3-319-94174-5. DOI:10.1007/978-3-319-94174-5_510.1007/978-3-319-94174-5_5 ↗
28. Hickey A.J., Mansour H.M., Telko M.J., Xu Z., Smyth H.D.C., Mulder T., McLean R., Langridge J., Papadopoulos D., Physical characterization of component particles included in dry powder inhalers. I. strategy review and static characteristics, Journal of Pharmaceutical Sciences, 96 (2007) 1282–1301. DOI:10.1002/jps.2091610.1002/jps.20916 ↗
29. Hufnagel S., Sahakijpijarn S., Moon C., Cui Z., III R.O.W., The development of thin-film freezing and its application to improve delivery of biologics as dry powder aerosols, KONA Powder and Particle Journal, 39 (2022) 176–192. DOI:10.14356/kona.202201010.14356/kona.2022010 ↗
30. Kaviratna A., Tian G., Liu X., Delvadia R., Lee S., Guo C., Evaluation of bio-relevant mouth-throat models for characterization of metered dose inhalers, AAPS PharmSciTech, 20 (2019) 130. DOI:10.1208/s12249-019-1339-610.1208/s12249-019-1339-6 ↗
31. Khoubnasabjafari M., Rahimpour E., Samini M., Jouyban-Gharamaleki V., Chen L., Chen D., Chan H.-K., Jouyban A., A new hypothesis to investigate bioequivalence of pharmaceutical inhalation products, DARU Journal of Pharmaceutical Sciences, 27 (2019) 517–524. DOI:10.1007/s40199-019-00250-x10.1007/s40199-019-00250-x ↗
32. Kugler Sz., Nagy A., Kerekes A., Veres M., Rigó I., Czitrovszky A., Determination of emitted particle characteristics and upper airway deposition of Symbicort® Turbuhaler® dry powder inhaler, Journal of Drug Delivery Science and Technology, 54 (2019) 101229. DOI:10.1016/j.jddst.2019.10122910.1016/j.jddst.2019.101229 ↗
33. Kuribayashi R., Myoenzono A., Takagi K., Hirota M., Current understanding of the equivalence evaluations for in vitro tests on generic dry powder inhaler drug products in Japan, European Journal of Drug Metabolism and Pharmacokinetics, 44 (2019) 743–745. DOI:10.1007/s13318-019-00561-z10.1007/s13318-019-00561-z ↗
34. Kuribayashi R., Yamaguchi T., Sako H., Takishita T., Takagi K., Bioequivalence evaluations of generic dry powder inhaler drug products: similarities and differences between Japan, USA, and the European Union, Clinical Pharmacokinetics, 56 (2017) 225–233. DOI:10.1007/s40262-016-0438-810.1007/s40262-016-0438-8 ↗
35. Lee S.L., Adams W.P., Li B.V., Conner D.P., Chowdhury B.A., Yu L.X., In vitro considerations to support bioequivalence of locally acting drugs in dry powder inhalers for lung diseases, The AAPS Journal, 11 (2009) 414–423. DOI:10.1208/s12248-009-9121-410.1208/s12248-009-9121-4 ↗
36. Louey M.D., Oort M.V., Hickey A.J., Standardized entrainment tubes for the evaluation of pharmaceutical dry powder dispersion, Journal of Aerosol Science, 37 (2006) 1520–1531. DOI:10.1016/j.jaerosci.2006.04.00210.1016/j.jaerosci.2006.04.002 ↗
37. Lyapustina S., Regulatory pitfalls and opportunities when repurposing for inhalation therapy, Advanced Drug Delivery Reviews, 133 (2018) 57–65. DOI:10.1016/j.addr.2018.04.01310.1016/j.addr.2018.04.013 ↗
38. Mitchell J., Newman S., Chan H.-K., In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review, AAPS PharmSciTech, 8 (2007) E1–E12. DOI:10.1208/pt080411010.1208/pt0804110 ↗
39. Newman S.P., Chan H.-K., In vitro/in vivo comparisons in pulmonary drug delivery, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 21 (2008) 77–84. DOI:10.1089/jamp.2007.064310.1089/jamp.2007.0643 ↗
40. Newman S.P., Chan H.-K., In vitro-in vivo correlations (IVIVCs) of deposition for drugs given by oral inhalation, Advanced Drug Delivery Reviews, 167 (2020) 135–147. DOI:10.1016/j.addr.2020.06.02310.1016/j.addr.2020.06.023 ↗
41. Olsson B., Borgström L., Lundbäck H., Svensson M., Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 26 (2013) 355–369. DOI:10.1089/jamp.2012.098610.1089/jamp.2012.0986 ↗
42. Pleasants R.A., Hess D.R., Aerosol delivery devices for obstructive lung diseases, Respiratory Care, 63 (2018) 708–733. DOI:10.4187/respcare.0629010.4187/respcare.06290 ↗
43. Rahimpour Y., Kouhsoltani M., Hamishehkar H., Alternative carriers in dry powder inhaler formulations, Drug Discovery Today, 19 (2014) 618–626. DOI:10.1016/j.drudis.2013.11.01310.1016/j.drudis.2013.11.013 ↗
44. Sahakijpijarn S., Moon C., Ma X., Su Y., Koleng J.J., Dolocan A., Williams R.O. III, Using thin film freezing to minimize excipients in inhalable tacrolimus dry powder formulations, International Journal of Pharmaceutics, 586 (2020) 119490. DOI:10.1016/j.ijpharm.2020.11949010.1016/j.ijpharm.2020.119490 ↗
45. Shi S., Hickey A.J., Multivariate data analysis as a semi-quantitative tool for interpretive evaluation of comparability or equivalence of aerodynamic particle size distribution profiles, AAPS PharmSciTech, 10 (2009) 1113–1120. DOI:10.1208/s12249-009-9303-510.1208/s12249-009-9303-5 ↗
46. Taki M., Ahmed S., Marriott C., Zeng X.-M., Martin G.P., The ‘stage-by-stage’ deposition of drugs from commercial single-active and combination dry powder inhaler formulations, European Journal of Pharmaceutical Sciences, 43 (2011) 225–235. DOI:10.1016/j.ejps.2011.04.01410.1016/j.ejps.2011.04.014 ↗
47. Tougas T.P., Christopher D., Mitchell J., Lyapustina S., Van Oort M., Bauer R., Glaab V., Product lifestyle approach to cascade impaction measurements, AAPS PharmSciTech, 12 (2011) 312–322. DOI:10.1208/s12249-011-9590-510.1208/s12249-011-9590-5 ↗
48. Tougas T.P., Christopher D., Mitchell J.P., Strickland H., Wyka B., Van Oort M., Lyapustina S., Improved quality control metrics for cascade impaction measurements of orally inhaled drug products (OIPs), AAPS PharmSciTech, 10 (2009) 1276–1285. DOI:10.1208/s12249-009-9312-410.1208/s12249-009-9312-4 ↗
49. Uddin S., Hossain M., Al Mamun A., Zaman S., Asaduzzaman,Rashid M., Pharmacopoeial standards and specifications for pharmaceutical aerosols: in-process and finished products quality control tests, Advances in Research, 6 (2016) 22442 (12pp). DOI:10.9734/AIR/2016/2244210.9734/AIR/2016/22442 ↗
50. US-FDA, Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products—Quality Considerations: Guidance for Industry, US Food and Drug Administration, Silver Spring, MD, 2018, FDA-2018-D-1098. accessed 20.07.2022.
51. VanDevanter D.R., Geller D.E., Tobramycin administered by the TOBI(R) Podhaler(R) for persons with cystic fibrosis: a review, Medical Devices: Evidence and Research, 4 (2011) 179–188. DOI:10.2147/MDER.S1636010.2147/MDER.S16360 ↗
52. Weers J., Clark A., The impact of inspiratory flow rate on drug delivery to the lungs with dry powder inhalers, Pharmaceutical Research, 34 (2017) 507–528. DOI:10.1007/s11095-016-2050-x10.1007/s11095-016-2050-x ↗
53. Wei X., Hindle M., Kaviratna A., Huynh B.K., Delvadia R.R., Sandell D., Byron P.R., In vitro tests for aerosol deposition. VI: realistic testing with different mouth-throat models and in vitro-in vivo correlations for a dry powder inhaler, metered dose inhaler, and soft mist inhaler, Journal of Aerosol Medicine and Pulmonary Drug Delivery, 31 (2018) 358–371. DOI:10.1089/jamp.2018.145410.1089/jamp.2018.1454 ↗
54. Wu X., Li X., Mansour H.M., Surface analytical techniques in solid-state particle characterization for predicting performance in dry powder inhalers, KONA Powder and Particle Journal, 28 (2010) 3–18. DOI:10.14356/kona.201000510.14356/kona.2010005 ↗
55. Yang T.T., Li S., Wyka B., Kenyon D., Drug delivery performance of the mometasone furoate dry powder inhaler, Journal of Aerosol Medicine, 14 (2001) 487–494. DOI:10.1089/0894268015274469510.1089/08942680152744695 ↗
56. Yazdi A.K., Smyth H.D.C., Carrier-free high-dose dry powder inhaler formulation of ibuprofen: physicochemical characterization and in vitro aerodynamic performance, International Journal of Pharmaceutics, 511 (2016) 403–414. DOI:10.1016/j.ijpharm.2016.06.06110.1016/j.ijpharm.2016.06.061 ↗
57. Zhang Y., Gilbertson K., Finlay W.H., In vivo-in vitro comparison of deposition in three mouth-throat models with Qvar(R) and Turbuhaler(R) inhalers, Journal of Aerosol Medicine, 20 (2007) 227–235. DOI:10.1089/jam.2007.058410.1089/jam.2007.0584 ↗
58. Ziffels S., Bemelmans N.L., Durham P.G., Hickey A.J., In vitro dry powder inhaler formulation performance considerations, Journal of Controlled Release, 199 (2015) 45–52. DOI:10.1016/j.jconrel.2014.11.03510.1016/j.jconrel.2014.11.035 ↗